Paclitaxel oral - Hanmi Pharmaceutical

Drug Profile

Paclitaxel oral - Hanmi Pharmaceutical

Alternative Names: Oral paclitaxel - Hanmi Pharmaceutical; Oraxol; Paclitaxel + HM 30181A; Paclitaxel + HM 30181AK-US

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex; Hanmi Pharmaceutical; PharmaEssentia Corporation; Zenith Technology Corporation
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Gastric cancer
  • Phase I Solid tumours

Most Recent Events

  • 27 Jan 2017 PharmaEssentia acquires the rights to develop and commercialise paclitaxel oral (Oraxol) in Vietnam (9213921; 9213637)
  • 18 Nov 2016 Athenex and Eli Lilly agree to conduct a phase Ib trial for Gastric cancer and Oesophageal cancer (Late-stage disease, Metastatic disease, Combination therapy, In adults, In the elderly) in USA and Asia (NCT02970539)
  • 01 Sep 2016 Kinex Pharmaceuticals (Athenex) completes a phase-I trial in Solid tumours (Late-stage disease) in USA (PO) (NCT01967043)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top